Cited by 82Genetics and Neurodevelopmental DisordersGenomics and Rare DiseasesEpigenetics and DNA Methylation

Structure of the MeCP2–TBLR1 complex reveals a molecular basis for Rett syndrome and related disorders

Open access
Kruusvee, Valdeko, Lyst, Matthew J., Taylor, Ceitidh, Tarnauskaitė, Žygimantė, Bird, Adrian P., Cook, Atlanta G.·2017·Proceedings of the National Academy of Sciences

Abstract

) gene. The majority of RTT missense mutations disrupt the interaction of the MeCP2 with DNA or the nuclear receptor corepressor (NCoR)/silencing mediator of retinoic acid and thyroid receptors (SMRT) corepressor complex. Here, we show that the "NCoR/SMRT interaction domain" (NID) of MeCP2 directly contacts transducin beta-like 1 (TBL1) and TBL1 related (TBLR1), two paralogs that are core components of NCoR/SMRT. We determine the cocrystal structure of the MeCP2 NID in complex with the WD40 domain of TBLR1 and confirm by in vitro and ex vivo assays that mutation of interacting residues of TBLR1 and TBL1 disrupts binding to MeCP2. Strikingly, the four MeCP2-NID residues mutated in RTT are those residues that make the most extensive contacts with TBLR1. Moreover, missense mutations in the gene for TBLR1 that are associated with intellectual disability also prevent MeCP2 binding. Our study therefore reveals the molecular basis of an interaction that is crucial for optimal brain function.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1700731114

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Six mutations in TBLR1 mapped to the WD40 domain of the protein and disrupted MeCP2-binding.

    “Notably, six of these mutations in TBLR1 mapped to the WD40 domain of the protein and disrupted MeCP2-binding [150].”

    From Rett syndrome: a neurological disorder with metabolic components (2018) · cites this paper as [150]

    The section “Disease-Associated TBLR1 Mutations Block MeCP2 Binding” (page unavailable) identifies six TBLR1 mutations and says all map to the WD40 domain. It demonstrates disrupted MeCP2 binding for two of those mutations, D369E and P444R, but does not establish that all six disrupt binding; the Discussion likewise says “at least two.” (LLM, conf=0.90)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kruusvee, V., Lyst, M. J., Taylor, C., Tarnauskaitė, Ž., Bird, A. P., & Cook, A. G.
Affiliations
  • Wellcome Centre for Cell Biology (GB)
  • Western General Hospital (GB)
Venue
Proceedings of the National Academy of Sciences
Published
2017-03-27
Volume
114
Issue
16
Pages
E3243-E3250
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2601670548
Cited by
82
References
2
Citations by year
2026: 5 · 2025: 5 · 2024: 17 · 2023: 9 · 2022: 7 · 2021: 8 · 2020: 9 · 2019: 10 · 2018: 9 · 2017: 3
FWCI
5.63
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
Funders
  • Wellcome Trust (091580, 107930, 092076, 095822, 108504)
  • Medical Research Council (G1000520/1)
  • Rett Syndrome Research Trust (4951)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords
MeCP2, TBL1, Rett syndrome, WD40 domain, protein-protein interaction, missense mutations, intellectual disability, co-crystal structure, brain function
MeSH terms
HeLa Cells, Humans, Nuclear Proteins, Protein Conformation, Repressor Proteins, Transducin, Rett Syndrome, Receptors, Cytoplasmic and Nuclear, Crystallography, X-Ray, Mutation, Missense, Methyl-CpG-Binding Protein 2, Nuclear Receptor Co-Repressor 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review